Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411480 | 1.00 | SLC18A3 (0.46) | SLC18A3SIGMAR1AKT1GNRHRMAPK1 | |
| SCHEMBL2354258 | 0.85 | AKT1 (0.43) | SLC18A3SIGMAR1AKT1GNRHRNOTUM | |
| SCHEMBL13519046 | 0.83 | ALDH1A1 (0.44) | SLC18A3SIGMAR1AKT1MAPK1NOTUM | |
| SCHEMBL22047676 | 0.82 | NOTUM (0.46) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL4975916 | 0.82 | SLC18A3 (0.56) | SLC18A3SIGMAR1HDAC1HDAC6HDAC8 | |
| SCHEMBL4975920 | 0.82 | SLC18A3 (0.56) | SLC18A3SIGMAR1HDAC1HDAC6HDAC8 | |
| SCHEMBL4974614 | 0.81 | HDAC1 (0.50) | SLC18A3SIGMAR1CYP2C19HDAC1HDAC6 | |
| SCHEMBL2625791 | 0.81 | HDAC1 (0.50) | SLC18A3SIGMAR1CYP2C19HDAC1HDAC6 | |
| SCHEMBL13519045 | 0.80 | SLC18A3 (0.42) | SLC18A3SIGMAR1AKT1NOTUMHDAC1 | |
| SCHEMBL4977380 | 0.76 | OPRL1 (0.58) | AKT1MAPK1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | SLC18A3 3734/4885SIGMAR1 10/4885AKT1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.